Thirdly, we only included cases that were visually amyloid‐positive on PET in this analysis because, in clinical practice, AD‐signature tau might not be considered for patients with CAA who have a visually amyloid‐negative scan; these patients may represent a subgroup with a milder or regional form of CAA. This evidence concerns the gene MAPT and Alzheimer disease.